Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

29 Mar 2006 07:02

Angle PLC29 March 2006 For Immediate Release 29 March 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: InnoMatica Ltd ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, InnoMatica Ltd ('InnoMatica'). In accordance with ANGLE's Progeny(R) process for creating new ventures,InnoMatica has secured intellectual property that is set to revolutionise theUS$1.2bn per annum global market for percussive power tools by reducing operatorexposure to vibration, the principal cause of medical conditions such asVibration White Finger (VWF). The technology has been developed over ten yearsby a team of leading engineers, academics from the University of Cambridge andmembers of the power tools industry. The scale of the vibration problem is substantial. In 2001, over 35% ofemployer's liability insurance claims were for Hand Arm Vibration Syndrome(HAVS), a debilitating condition caused by exposure to hand transmittedvibration. The Health and Safety Executive (HSE) estimates that there are around300,000 sufferers of VWF, the most common form of HAVS, in the UK, with around 2million people regularly exposed to high levels of vibration. Costs of settlinga single VWF claim can exceed £200,000. Since the implementation throughout Europe of the Physical Agents (Vibration)Directive (approved by the UK Parliament as The Control of Vibration at WorkRegulations, July 2005), employers have been bound to adhere to specific limitson employee exposure to vibration in the workplace. The only method ofsignificantly reducing the vibrations generated by percussive power tools, suchas road breakers, is by increasing the mass of the tool; yet practical andregulatory issues prevent the movement of such heavy tools. As a result,employers have had to either limit the time a single employee may use a tool oruse deliberately underpowered tools in order to comply with the regulations. InnoMatica holds the solution to this problem in the form of its Variable MassTechnology (VMtechnologyTM). This technology reduces tool vibration to a levelthat allows a single operator to use a powerful percussive power tool for up tofour times longer than existing products. This not only removes the need fortime limits or power reduction, but also provides the operator with a much saferand easier to use tool. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering, seeking a return on itsinvestment in the medium term. ANGLE expects to invest up to £400,000 in theProgeny(R) venture, which is presently wholly owned by ANGLE. Once InnoMaticahas exercised its option to acquire the technology, ANGLE's equity stake in theCompany will be 61%. ANGLE's Chief Executive, Andrew Newland, said: "The power tools and construction industries are worth US$1.2bn per annum, andthey have long awaited a solution to the injuries caused from vibration powertools. We are delighted to be at the forefront of a technology that dramaticallyenhances productivity, not only solving the financial and legislative issues butalso addressing human safety." Chief Technology Officer of InnoMatica, Dott. Giovanni Bisutti, said: "InnoMatica's technology provides a genuine new standard for health, safety,productivity and operator comfort in percussive power tools. We intend toaddress the major legislative and productivity issues currently facing theindustry." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.